MPT: Unexpected Results with Direct Thrombin Inhibitor in PCI

ACC Conference Reporter

ESC 2017 | BARCELONA — Bivalirudin (Angiomax) flipped in a trial against heparin, as it unexpectedly didn't reduce bleeding nor raise stent thrombosis rates for acute MI patients undergoing percutaneous coronary intervention (PCI) in the VALIDATE-SWEDEHEART trial, according to researchers here. Read More >>>


< Back to Listings